SCHEMBL443057

SCHEMBL443057

COc1ccc(N)cc1OCCNC(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 1/20 0.51
MTNR1B P49286 1/20 0.51
ALDH1A1 P00352 4/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
TP53 P04637 1/20 0.48
PDE4A P27815 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4C Q08493 1/20 0.46
PDE4D Q08499 1/20 0.46
KDM4E B2RXH2 1/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
KMT2A Q03164 3/20 0.44
NPC1 O15118 2/20 0.44
HSP90AA1 P07900 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
LMNA P02545 1/20 0.44
SMPD1 P17405 1/20 0.43
HPGD P15428 1/20 0.43
BRD4 O60885 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1531286 0.94 ALDH1A1 (0.54) MTNR1AMTNR1BALDH1A1L3MBTL1KDM4E
SCHEMBL12275269 0.92 KDM4E (0.47) MTNR1AMTNR1BALDH1A1L3MBTL1TP53
SCHEMBL1669867 0.87 KDM4E (0.53) MTNR1AMTNR1BALDH1A1L3MBTL1KDM4E
SCHEMBL7449161 0.83 CA12 (0.50) MTNR1AMTNR1BALDH1A1TP53PDE4A
SCHEMBL7072684 0.80 MTNR1A (0.77) MTNR1AMTNR1BGAAKMT2ANPC1
SCHEMBL1531347 0.80 KDM4E (0.49) MTNR1AMTNR1BALDH1A1L3MBTL1PDE4A
SCHEMBL13244152 0.79 LMNA (0.54) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL3020849 0.79 CA12 (0.51) BRD4
SCHEMBL6675153 0.78 MTNR1A (0.49) MTNR1AMTNR1BALDH1A1HPGD
SCHEMBL13214929 0.78 MAPT (0.56) ALDH1A1PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394955-B2 2,4 (4,6) pyrimidine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2013-03-12 US disclosed
US-8148388-B2 2,4 (4,6) pyrimidine derivatives JANSSEN PHARMACEUTICA, N.V. (BE) 2012-04-03 US disclosed
US-20120065395-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES FREYNE EDDY JEAN EDGARD (BE) 2012-03-15 US disclosed
US-20100160310-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2010-06-24 US disclosed
EP-1824856-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-29 EP disclosed
WO-2006061415-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065395-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES NR0B1, NR1H3, NCOA3 MTNR1A 142/4885MTNR1B 250/4885ALDH1A1 1457/4885
US-20100160310-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES NR1H3, NR1H2, NR0B1 MTNR1A 133/4885MTNR1B 231/4885ALDH1A1 1741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.